Results 11 to 20 of about 5,463 (146)

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma

Haematologica, 2017
The GAUDI study assessed safety and preliminary efficacy of induction therapy with obinutuzumab plus chemotherapy, followed by maintenance therapy with obinutuzumab alone, in previously untreated patients with follicular lymphoma.
Andrew Grigg, Martin J.S. Dyer, Marcos González Díaz, Martin Dreyling, Simon Rule, Guiyuan Lei, Andrea Knapp, Elisabeth Wassner-Fritsch, Paula Marlton   +8 more
doaj   +1 more source

Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study

Haematologica, 2018
The safety of obinutuzumab, alone or with chemotherapy, was studied in a non-randomized, open-label, non-comparative, phase IIIb study (GREEN) in previously untreated or relapsed/refractory chronic lymphocytic leukemia.
Véronique Leblond, Melih Aktan, Christelle M. Ferra Coll, Caroline Dartigeas, Jens Kisro, Marco Montillo, João Raposo, Jean-Louis Merot, Susan Robson, Ekaterina Gresko, Francesc Bosch, Stephan Stilgenbauer, Robin Foà   +12 more
doaj   +1 more source

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

HemaSphere, 2023
The phase III GALLIUM trial assessed the safety and efficacy of obinutuzumab-based versus rituximab-based immunochemotherapy in patients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL).
William Townsend, Wolfgang Hiddemann, Christian Buske, Guillaume Cartron, David Cunningham, Martin J.S. Dyer, John G. Gribben, Elizabeth H. Phillips, Martin Dreyling, John F. Seymour, Andrew Grigg, Judith Trotman, Tong-Yu Lin, Xiao-Nan Hong, Dirk Kingbiel, Tina G. Nielsen, Andrea Knapp, Michael Herold, Robert Marcus   +18 more
doaj   +1 more source

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab

Hematology/Oncology and Stem Cell Therapy, 2017
Objective/background: Membranoproliferative glomerulonephritis (MPGN) is a common extramedullary renal presentation in chronic lymphocytic leukemia (CLL) and can present with either a frank renal failure or proteinuria.
Punit Jain, Rashmi Kanagal-Shamanna, William Wierda, Alessandra Ferrajoli, Michael Keating, Nitin Jain   +5 more
doaj   +1 more source

Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma

Haematologica, 2016
Obinutuzumab (GA101) is a type II, glycoengineered anti-CD20 monoclonal antibody for the treatment of hematologic malignancies. Obinutuzumab has mechanisms of action that are distinct from those of rituximab, potentially translating into improved ...
Guillaume Cartron, Florence Hourcade-Potelleret, Franck Morschhauser, Gilles Salles, Michael Wenger, Anna Truppel-Hartmann, David J. Carlile   +6 more
doaj   +1 more source

The B cell death function of obinutuzumab-HDEL produced in plant (Nicotiana benthamiana L.) is equivalent to obinutuzumab produced in CHO cells. [PDF]

PLoS ONE, 2018
Plants have attracted attention as bio-drug production platforms because of their economical and safety benefits. The preliminary efficacy of ZMapp, a cocktail of antibodies produced in N.
Jin Won Lee, Woon Heo, Jinu Lee, Narae Jin, Sei Mee Yoon, Ki Youl Park, Eun Yu Kim, Woo Taek Kim, Joo Young Kim   +8 more
doaj   +1 more source

Signal management and risk minimization strategy: a case study on obinutuzumab and non-overt disseminated intravascular coagulation

Frontiers in Drug Safety and Regulation, 2023
Introduction: In December 2020, the Italian Medicines Agency (AIFA) in collaboration with the Italian Regional Centers of Pharmacovigilance evaluated four individual case safety reports (ICSRs) reporting obinutuzumab and non-overt disseminated ...
Giulia Valdiserra, Nadia Mores, Rosalba Elisabetta Rocchi, Laura Sottosanti, Patrizia Felicetti, Pasquale Marchione, Luca Laurenti, Alberto Fresa, Giampaolo Bucaneve, Emiliano Cappello, Marco Bonaso, Sara Ferraro, Irma Convertino, Marco Tuccori, Marco Tuccori   +14 more
doaj   +1 more source

Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients

Transplantation Direct, 2023
Background. The THEORY study evaluated the effects of single and multiple doses of obinutuzumab, a type 2 anti-CD20 antibody that induces antibody-dependent cell-mediated cytotoxicity and direct cell death, in combination with standard of care in ...
Cary M. Looney, MS, Aaron Schroeder, BS, Erica Tavares, BSN, Jay Garg, MD, MBA, Thomas Schindler, PhD, Flavio Vincenti, MD, Robert R. Redfield, MD, Stanley C. Jordan, MD, Stephan Busque, MD, E. Steve Woodle, MD, Jared Khan, MS, Jeffrey Eastham, MS, Sandrine Micallef, PhD, Cary D. Austin, MD, PhD, Alyssa Morimoto, PhD   +14 more
doaj   +1 more source

Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia

SAGE Open Medical Case Reports, 2019
Obinutuzumab is used for the treatment of chronic lymphocytic leukemia. So far there are no data of using this for retreatment in patients who have received it previously.
Sharad Khurana, Salman Ahmed, Victoria R Alegria, Sonikpreet Aulakh, Meghna Ailawadhi, Anshika Singh, Asher Chanan-Khan, Sikander Ailawadhi   +7 more
doaj   +1 more source

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

British Journal of Clinical Pharmacology, EarlyView.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen   +3 more
wiley   +1 more source